| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hypnotics and opioids interact synergistically to block responses to surgery and different dose combinations may be used to provide adequate anesthesia. In this study, we sought to determine the optimal concentrations of propofol and sufentanil, given by target-controlled infusions, to ensure hemodynamic stability, adequate hypnosis (assessed by electroencephalogram bispectral indexTM), and fast recovery for a moderately painful operation. Forty-five patients, ASA physical status I or II, undergoing thyroidectomy, were randomly assigned to a sufentanil target concentration (STC) that was maintained throughout surgery (0.1, 0.2, or 0.3 ng/mL). The propofol target concentration was adjusted to keep mean arterial blood pressure within 30% of a reference value, and bispectral indexTM between 40 and 60. Adequate anesthesia was obtained in all groups. Hypertension and clinically dangerous movements were more frequent with the small STC, and hypotension requiring treatment was more frequent with the large STC. Propofol target concentration during surgery decreased significantly with increasing STC (median at thyroid removal 5.0, 4.0, and 2.5 µg/mL, respectively) as well as the propofol consumption (740, 668, 474 mg/h). The 0.3 ng/mL STC significantly delayed the return of spontaneous breathing. IMPLICATIONS: Given as a target-controlled infusion for thyroid surgery, sufentanil 0.3 ng/mL for intubation and 0.2 ng/mL during surgery, combined with propofol 4 µg/mL (corresponding to a maintenance infusion rate of approximately 710 mg · kg-1 · h-1), is recommended to ensure both optimal intraoperative stability and fast recovery.
Anesthesia is a complex state, involving unconsciousness, amnesia, and loss of response to noxious stimulation (1). The first two components are mainly controlled by hypnotics and the third by opioids. A synergistic interaction has been demonstrated between both drugs classes, each of them having a dose-dependent sparing effect on the requirements of the other. Synergism is more pronounced for blocking reactions to noxious stimuli than for loss of consciousness (LOC) (2). Thus, different dose combinations of hypnotics and opioids may be suitable for maintaining adequate anesthesia. The optimal combination could be based on maximal synergism (i.e., minimal doses of both drugs and minimal side effects from each) (3), the fastest recovery (4), or the combination associated with the lowest cost. Propofol-opioid combinations for total IV anesthesia (TIVA) have been extensively studied (57). However, most of the published data were extrapolated to sufentanil from clinical studies using other opioids, assuming a fixed potency ratio (e.g., sufentanil/alfentanil = 630) (4). Some studies focused on LOC, or response to intubation and skin incision. Whereas propofol-opioid combinations have been extensively studied for intraabdominal surgery (4), interactions between these drugs during TIVA for thyroid surgery have not been described. Because thyroid surgery involves a very sensitive area, drug requirements are often unpredictable. Also, there is increased risk for postoperative nausea and vomiting after thyroid surgery, and the antiemetic effect of propofol could be an advantage. In this study, our aim was to assess the clinical use of propofol-sufentanil TIVA for thyroid surgery, and to quantify the influence of the sufentanil concentration on propofol requirements, stability of anesthesia, and recovery.
Inclusion Criteria With approval of the local Medical Ethics Committee and after written informed consent, male or female patients, aged between 18 and 70 yr, and scheduled for thyroid surgery, were eligible. Patients with at least one of the following criteria were excluded: ASA physical status >II, hyperthyroidism, preoperative treatment with either opioids or antihypertensive medication, drug or high alcohol consumption, expected difficult intubation, pregnant women, known allergy to propofol or µ agonist opioids, and inclusion in another clinical study in the previous 30 days. Patients were randomly assigned to 1 of 3 groups, to receive a fixed sufentanil target concentration (STC) of 0.1, 0.2, or 0.3 ng/mL. Randomization was done by blocks of six patients using PIGAS software and stratified to have a similar sex ratio in the three groups. The study was open, i.e., the investigator was aware of the STC.
Protocol Sufentanil (diluted to 1 µg/mL) was administered IV as an effect-site target-controlled infusion (TCI) using Stanpump software (Dr. S. L. Shafer, Stanford University, CA1) controlling a Graseby 3400TM syringe pump. The Gepts pharmacokinetic model (three-compartment model, not adjusted for weight, age, or sex) was used (8). The sufentanil TCI was started after 3 min of preoxygenation, at the randomized STC. Then, a propofol TCI was started with an initial target plasma concentration of 4 µg/mL, using a DiprifusorTM (Astra Zeneca, London, UK) based on a three-compartment pharmacokinetic model adjusted to weight (9). If LOC was not obtained after 3 min, the target propofol concentration was increased by steps of 12 µg/mL every 2 min. After LOC, atracurium (0.5 mg/kg) was given IV to facilitate orotracheal intubation, performed 2 to 5 min later. Then, the lungs of the patients were ventilated with a 50:50 mixture of air and oxygen and ventilation was adjusted to maintain PETCO2 between 30 and 35 mm Hg. The STC was maintained constant until thyroid removal, then stopped during immediate histologic examination. If the histology showed a benign pathology, skin closure was completed with propofol only. In case of malignancy, sufentanil TCI was started again at the initial STC to complete appropriate lymph node dissection. Adequate anesthesia was defined by all the following conditions being met: 1. mean arterial blood pressure (MBP) between 70% and 130% of a reference value defined as the mean of three measurementspreoperative visit, time of preanesthetic medication, and the preinduction value, 2. BISTM between 40 and 60, and 3. no somatic responses (movements or swallowing) to surgical stimulation. Propofol, fluid administration, and other drugs were given as indicated to achieve those criteria according to a decision matrix described in Table 1 (10). Additional atracurium was administered when movements disturbed the surgeon despite adequate BISTM and MBP values.
Propofol TCI was stopped at the end of skin closure. Then, every patient was tested at regular intervals to detect recovery (response to verbal commands) and adequate spontaneous ventilation (respiratory rate >8/min, minute ventilation >4 L/min). Once spontaneous ventilation was established and a positive response to verbal command obtained, the trachea was extubated and the patient transferred to the recovery room.
Postoperative Care
Data Recording and Analysis Quality of anesthesia was assessed during separate periods: from induction to incision, from incision to thyroid removal, and during closure, by the following criteria:
Hemodynamic and BISTM response to intubation were specifically analyzed. Propofol effect-site concentrations necessary to achieve adequate anesthesia was analyzed: 1) before intubation, after LOC, 2) before incision, and 3) at thyroid removalduring the stimulating surgical period. Total doses of propofol and sufentanil were calculated per patient, and normalized as mass unit/h. During recovery, three end-points were distinguished: 1)adequate spontaneous ventilation, 2) positive response to a verbal command, and 3) extubation (assuming both other end-points were achieved). For each end-point, the time from the end of anesthesia (propofol target concentration set to 0) and the predicted effect-site residual propofol and sufentanil concentrations were analyzed. Twenty-four hours postoperatively, analgesic consumption and the incidence of nausea and vomiting were recorded and each patient was interviewed for global satisfaction, any recall of intraoperative events, pain score, and possible side effects. The number of patients in each group was calculated based on an expected reduction of propofol requirement of 60% (2). With an interindividual variability of 50%, 15 patients per group should be necessary to achieve a power of 80%. Because the small number of patients in each group did not provide normal distribution of the variables, all results were expressed as median and range. Patients characteristics (age, weight) as well as all quantitative variables were compared among the three STC groups by a using the nonparametric Kruskal-Wallis test (11). Qualitative variables were compared by using an exact Fisher test. A P value < 0.05 was considered as statistically significant.
Pharmacodynamic Modeling
Solving this equation allows the propofol concentration to be expressed as a function of sufentanil concentration:
If the interaction between drugs is purely additive (no synergy), the interaction coefficient e = 0, and the equation becomes:
The predicted concentrations before intubation, before incision, at thyroid removal, and during recovery were fitted to both additive and nonadditive models by a simple least squares method using the solver function of Microsoft Excel version 7.0 for Windows 95. As the nonadditive model estimated one more variable ("e") than the additive model, the residual sum of squares of both fitted curves were compared by using a
Forty-five patients were included (15 patients in each group). All completed the study without severe adverse events. Patient characteristics: age (46 yrs; range, 2570), weight (62 kg; range, 46112), or type of surgery did not differ among the groups. The majority of patients were women (35/45) and were undergoing total thyroidectomy (31 versus 14 thyroid lobectomy). The duration of anesthesia was similar for both types of surgery (138 min; range, 76370). The number of patients undergoing lymph node dissection, which is known as a cause of bradycardia, was similar among the groups (9/45).
Quality and Stability of Anesthesia
The time from induction to incision was similar in all groups (27 min; range, 1749). The level of anesthesia was adequate during the whole period for most of the patients: inadequate anesthesia episodes, defined by either BISTM or MBP out of the desired range, was not observed for 21 patients, once for 17 patients, and 2 or 3 times for the remaining 7 patients. There were no differences among the groups.
During Surgery, Until Thyroid Removal. Hemodynamic stability differed significantly with the STC (Table 3). Hypertension requiring treatment, and tachycardia >120 bpm, were significantly more frequent in the small STC group, whereas hypotension and ephedrine treatment (6-mg bolus, repeated if necessary after the next MBP measurement) were more frequent in the large STC group. The patients given intermediate STC (0.2 ng/mL) had fewer hemodynamic side effects than the other two groups.
The overall number of somatic responses was not statistically different among the groups. Nevertheless, shoulder movements or swallowing during neck dissection severe enough to disturb the surgeon occurred only in the small STC group and two patients in this group required additional neuromuscular blockade to allow surgery to resume, despite adequate BISTM values. Slight movement, not interfering with surgery, occurred in one patient in the intermediate STC group but in none in the largest STC group.
During Histologic Analysis, Local Hemostasis, and Closure.
Influence of STC on Propofol Requirements
Just before skin incision, both target and effect-site propofol concentrations decreased significantly with increasing STC (P < 0.005, Fig. 1, middle), despite identical median values of 4 µg/mL: with 0.1 ng · mL-1 STC, propofol concentration was always 4 µg · mL-1 (n = 10) or more; with 0.2 ng · mL-1, 3 patients had a propofol concentration <4 µg · mL-1 1 and 2 patients > 4 µg · mL-1; and with 0.3 ng · mL-1, propofol concentration was 4 µg · mL-1 (n = 6) or less for all patients. At thyroid removal, again, the propofol concentration decreased significantly with increasing STC (P < 0.001, Fig. 1, bottom). The median propofol target at the end of thyroid removal was respectively 5.0, 4.0, and 2.5 µg/mL. Total propofol consumption decreased significantly by 10% with increasing STC from 0.1 to 0.2 ng/mL, and by 36% when STC increased from 0.1 to 0.3 ng/mL (Table 4).
Recovery and Postoperative Analgesia Recovery Times. Time to resume adequate spontaneous ventilation differed significantly with STC (Table 4). Small and intermediate STC groups recovered similarly, and 1 patient in the smallest STC group breathed spontaneously 12 min before stopping the propofol infusion at an effect-site concentration of 4.6 µg/mL. The time to adequate spontaneous ventilation was significantly prolonged in the large STC group and 1 patient was apneic for 39 min after the end of surgery. The times to respond to verbal commands and to extubation of the trachea did not differ significantly among groups. Nevertheless, the patient who was apneic for 39 min in the large STC group could only be extubated 71 min after the end of the propofol TCI.
Effect-Site Concentration at the Different Recovery End Points.
Postoperative Care. Morphine consumption during the first 2 h after surgery was small and similar in the 3 STC groups: 24 patients required no morphine (respectively 9, 7, and 8 patients). The other 21 patients required a median dose of 6 mg (range, 315 mg). During the next 22 h, 32 patients required no morphine, 4 patients required 510 mg, and the morphine consumption was not recorded for the remaining 9 patients. Paracetamol consumption ranged from 0 to 8 g/24 h, with a median value of 4 g/24 h in all groups. The incidence of PONV was 33% in the recovery room and 27% in the next 22 h, with no difference among the groups. Of the 37 patients questioned on the day after surgery, 18 were very satisfied with their anesthesia, 14 were satisfied, 5 were moderately satisfied, and none was unhappy, without any difference related to STC.
Propofol-Sufentanil Interaction Modeling. The correlation between STC and propofol predicted concentration was not statistically significant among groups before intubation (r = 0.16 with the additive model versus 0.18 with the interaction model) but was statistically significant before incision (r = 0.46 whatever the model, P < 0.01) and at thyroid removal (r = 0.63 with the additive model and 0.64 with interaction model, P < 0.01). In other words, in the range of concentrations studied, increasing the STC linearly decreased propofol requirement, without a demonstrated synergistic interaction.
This study demonstrated that a propofol-sufentanil TCI is suitable for thyroid surgery, with STC between 0.1 and 0.3 ng/mL. It also showed that increasing STC had little influence on BISTM and propofol requirement before incision, but influenced hemodynamic stability and propofol doses during the noxious stimulations of surgery, and may have delayed the early recovery. LOC was obtained with a target propofol concentration of 4 µg/mL in 30 of 45 patients (67%). This result is consistent with previous studies (13) and with the logistic model published by Schraag et al. (14). According to this model, the theoretical probability for LOC with propofol 3.5 µg/mL ranged between 44% (combined with 0.1 ng/mL sufentanil) and 76% (with 0.3 ng/mL). Achieving 95% probability of LOC would theoretically require an initial propofol target concentration >5 µg/mL (14) or 6 µg/mL (2). Such targets may be chosen for patients requiring a rapid induction, and in whom overdosage does not introduce a major cardiovascular risk. In other situations, an initial target of 4 µg/mL, followed by up-titration until LOC, can ensure 100% success without hemodynamic side effects, as shown in our study. The lack of a statistically significant influence of STC on the propofol effect-site concentration required for LOC may be attributable to an insufficient number of patients relative to the variability, but may support the fact that the influence of opioids on sedation is minor (15). This weak influence of opioids on sedation in the absence of noxious stimuli has also been reported when using BISTM monitoring to assess the level of sedation or anesthesia (1618).
Response to Intubation
Optimal Combination for Thyroid Surgery Minor surgery could be performed with propofol concentrations >3 µg/mL combined with meperidine, whereas major surgery required propofol target >4 µg/mL (20). When combined with sufentanil with an STC of 0.1 ng/mL, abdominal surgery required at least 5 µg/mL propofol, decreasing to 3 µg/mL propofol when combined with an STC of 0.3 ng/mL (5). These requirements are similar to our results, suggesting that thyroid surgery is closer to visceral than to peripheral surgery regarding drug requirements. As expected, increasing STC significantly decreased propofol requirements, as well as the interpatient variability in the propofol requirements (Fig. 1, bottom). Within the range of sufentanil concentrations studied, synergism could not be demonstrated, whereas most of the published studies reported a ceiling effect on propofol-opioids interactions (4,6,7,21). This difference may be attributable to a too large or too narrow range of opioid concentrations studied. It may also be more marked when considering responses to very painful stimuli such as during abdominal (4) or orthopedic surgery (21). Although adequate anesthesia could be obtained with all STC combined with propofol, the incidence of "inadequate anesthesia," as defined by Glen (22) differed markedly with STC. Whereas BISTM stability was similar for all STC, hemodynamic stability from incision until thyroid removal showed a clear benefit of 0.2 ng/mL STC compared with both other concentrations studied (Table 3). Frequent motor responses to surgical stimulation in patients receiving sufentanil 0.1 ng/mL (4/15 patients) suggests that this concentration cannot be recommend. None of the patients who moved had any recall of intraoperative events, which was consistent with adequate BISTM values (23) suggesting that movement may have other causes than awareness, involving subcortical or medullar structures. Motor response during surgery may have been underestimated because of a partial neuromuscular blockade. Unfortunately, neuromuscular blockade was not monitored in our study. However, surgery started 16 to 48 minutes after the induction of anesthesia and lasted 54332 minutes, and was similar among STC groups, and all movements were observed during final neck dissection. However, a partial neuromuscular recovery (<50% block) could be expected from 45 minutes after a 0.5 mg/kg atracurium bolus (simulation performed retrospectively with Stanpump software). In other words, all patients were expected to be able to move during the surgery period, and similarly among groups.
Recovery
Rapid recovery is usually desirable after short surgical procedures. Sufentanil has a shorter context sensitive half-time than fentanyl or alfentanil for infusions lasting <68 hours (24). Our results were consistent with this feature but emphasize that this "shortest" recovery time may exceed half an hour. Remifentanil, because of its ultra-short context sensitive half-time, which is virtually independent of the duration of infusion, might be a better choice of opioid when a rapid recovery is indicated (4,25). However, sufentanil is an acceptable option as long as STC remains We conclude that TIVA combining propofol and sufentanil in a TCI mode is suitable for thyroid surgery. An STC of at least 0.3 ng/mL should be chosen for intubation combined with a target propofol concentration of 4 µg/mL or larger, if necessary, to achieve LOC. During surgery, an STC of 0.2 ng/mL seemed optimal to ensure hemodynamic stability, lack of movement, and fast recovery, combined with a propofol target concentration of 4 µg/mL.
Supported for the cost of the study by the Janssen-Cilag Company, Issy-les-Moulineaux, France. We acknowledge Mrs. Joret (Janssen-Cilag), Dr. Laplanche, Mrs. Mercier, Mrs. Delicourt, and Dr. Treich (Institut Gustave Roussy) for their help on data management.
Presented as abstracts at the Société Française dAnesthésie et Réanimation, Paris, September 2000, and at the American Society of Anesthesiologists, San Francisco, October 2000.
1 Software graciously available at http://anesthesia.stanford. edu/pkpd.
This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|